Toll Free: 1-888-928-9744
Published: Oct, 2016 | Pages:
53 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Ageing - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ageing - Pipeline Review, H2 2016, provides an overview of the Ageing (Metabolic Disorders) pipeline landscape. Ageing is the accumulation of changes in a person over time. Symptoms include stooped posture, constipation, and increased susceptibility to infection, risk of heat stroke or hypothermia, decrease in visual acuity, wrinkling and sagging skin, and diminished peripheral vision. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ageing - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Ageing (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Ageing (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Ageing and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 5 and 3 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively for Ageing. Ageing (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Ageing (Metabolic Disorders). - The pipeline guide reviews pipeline therapeutics for Ageing (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Ageing (Metabolic Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Ageing (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Ageing (Metabolic Disorders) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Ageing (Metabolic Disorders). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Ageing (Metabolic Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Ageing Overview 7 Therapeutics Development 8 Pipeline Products for Ageing - Overview 8 Pipeline Products for Ageing - Comparative Analysis 9 Ageing - Therapeutics under Development by Companies 10 Ageing - Therapeutics under Investigation by Universities/Institutes 11 Ageing - Pipeline Products Glance 12 Clinical Stage Products 12 Early Stage Products 13 Ageing - Products under Development by Companies 14 Ageing - Products under Investigation by Universities/Institutes 15 Ageing - Companies Involved in Therapeutics Development 16 Generon (Shanghai) Corporation Ltd. 16 Mapreg S.A.S. 17 RepliCel Life Sciences, Inc. 18 RXi Pharmaceuticals Corporation 19 Saje Pharma, LLC 20 Theravasc, Inc. 21 Ageing - Therapeutics Assessment 22 Assessment by Monotherapy Products 22 Assessment by Target 23 Assessment by Mechanism of Action 25 Assessment by Route of Administration 27 Assessment by Molecule Type 29 Drug Profiles 31 AGS-499 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 BQ-A - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 Drugs for Ageing - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 F-899 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 MAP-46 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 MG-29 - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 MMP-26051 - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 MMP-26052 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 RCS-01 - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 sirolimus - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 sodium nitrite SR - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 SPL-891.1 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 TM-5441 - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 Ageing - Dormant Projects 46 Ageing - Product Development Milestones 47 Featured News & Press Releases 47 Apr 20, 2016: RepliCel Life Sciences Finishes Enrolment for its Skin Rejuvenation Clinical Trial 47 Dec 17, 2015: RepliCel Announces Completion of First Injections in Clinical Trial of RCS-01 for Skin Aging and UV-Damaged Skin 47 Sep 15, 2015: RepliCel Life Sciences Announces Initiation of Clinical Site and Participant Recruitment for European Skin Aging Study 48 Jul 21, 2015: RepliCel Receives Two Important Approvals for Dermal Rejuvenation Clinical Trial 49 Feb 23, 2015: RepliCel Submits Clinical Trial Application for its Dermatological Clinical Trial 50 Oct 09, 2014: RepliCel to Present Commercial and Clinical Update on RCS-01 at BioJapan 2014 World Business Forum 51 Appendix 52 Methodology 52 Coverage 52 Secondary Research 52 Primary Research 52 Expert Panel Validation 52 Contact Us 52 Disclaimer 53
List of Tables
Number of Products under Development for Ageing, H2 2016 8 Number of Products under Development for Ageing - Comparative Analysis, H2 2016 9 Number of Products under Development by Companies, H2 2016 10 Number of Products under Investigation by Universities/Institutes, H2 2016 11 Comparative Analysis by Clinical Stage Development, H2 2016 12 Comparative Analysis by Early Stage Development, H2 2016 13 Products under Development by Companies, H2 2016 14 Products under Investigation by Universities/Institutes, H2 2016 15 Ageing - Pipeline by Generon (Shanghai) Corporation Ltd., H2 2016 16 Ageing - Pipeline by Mapreg S.A.S., H2 2016 17 Ageing - Pipeline by RepliCel Life Sciences, Inc., H2 2016 18 Ageing - Pipeline by RXi Pharmaceuticals Corporation, H2 2016 19 Ageing - Pipeline by Saje Pharma, LLC, H2 2016 20 Ageing - Pipeline by Theravasc, Inc., H2 2016 21 Assessment by Monotherapy Products, H2 2016 22 Number of Products by Stage and Target, H2 2016 24 Number of Products by Stage and Mechanism of Action, H2 2016 26 Number of Products by Stage and Route of Administration, H2 2016 28 Number of Products by Stage and Molecule Type, H2 2016 30 Ageing - Dormant Projects, H2 2016 46
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.